{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:25:55Z","timestamp":1767374755708,"version":"3.37.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA011064"],"award-info":[{"award-number":["DA011064"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serotonin 1B receptor (5-HT<jats:sub>1B<\/jats:sub>R) agonists enhance cocaine intake in rats during daily self-administration but attenuate cocaine intake after prolonged abstinence. Here we investigated whether the less selective but clinically available 5-HT<jats:sub>1D\/1B<\/jats:sub>R agonist, zolmitriptan, produces similar effects. Male and free-cycling female Sprague-Dawley rats were trained to lever press for cocaine (0.75\u2009mg\/kg, i.v.) or sucrose (45\u2009mg pellet) reinforcement until performance rates stabilized. Rats then received zolmitriptan (3.0, 5.6, and 10\u2009mg\/kg, s.c.) prior to testing for its effects on response and reinforcement rates. Under cocaine testing conditions, rats had access to the training dose for the first hour followed by a lower cocaine dose (0.075\u2009mg\/kg, i.v.) for the second hour. Zolmitriptan decreased cocaine intake at both cocaine doses and in both sexes even without a period of abstinence and without altering sucrose intake. A separate group of rats underwent identical training procedures and were tested for effects of the selective 5-HT<jats:sub>1B<\/jats:sub>and 5-HT<jats:sub>1D<\/jats:sub>receptor antagonists, SB224289 (3.2, 5.6, and 10\u2009mg\/kg, s.c.) and BRL15572 (0.3, 1.0, and 3.0\u2009mg\/kg, i.p.), respectively, alone or in combination with zolmitriptan (5.6\u2009mg\/kg, s.c.) under identical cocaine testing procedures as above. The zolmitriptan-induced decrease in cocaine intake was reversed by SB224289 and to a lesser extent by BRL15572, suggesting that the effects of zolmitriptan involve both 5-HT<jats:sub>1B<\/jats:sub>and 5-HT<jats:sub>1D<\/jats:sub>receptors. Neither zolmitriptan, SB224289, or BRL15572 altered locomotor activity at the doses effective for modulating cocaine intake. These findings suggest that zolmitriptan has potential for repurposing as a treatment for cocaine use disorders.<\/jats:p>","DOI":"10.1038\/s41398-020-00956-6","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T18:05:54Z","timestamp":1596477954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical support for the therapeutic potential of zolmitriptan as a treatment for cocaine use disorders"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-1644","authenticated-orcid":false,"given":"Raul","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha N.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delaram","family":"Charmchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie M.L.","family":"Sprout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan S.","family":"Pentkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-3708","authenticated-orcid":false,"given":"Janet L.","family":"Neisewander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"956_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lpm.2013.01.069","volume":"43","author":"L Karila","year":"2014","unstructured":"Karila, L. et al. Cocaine addiction: current data for the clinician. Med. Press 43, 9\u201317 (2014).","journal-title":"Med. Press"},{"key":"#cr-split#-956_CR2.1","unstructured":"Hughes, A., Williams, M. R., Lipari, R. N. & Van Horn, S. State estimates of past year cocaine use among young adults: 2014 and 2015. In: The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US)"},{"key":"#cr-split#-956_CR2.2","unstructured":"2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK424783\/ (2016)."},{"key":"956_CR3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","volume":"68","author":"M Kariisa","year":"2019","unstructured":"Kariisa, M., Scholl, L., Wilson, N., Seth, P. & Hoots, B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential \u2014 United States, 2003\u20132017. Morb. Mortal. Wkly Rep. 68, 388\u2013395 (2019).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"956_CR4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1471-4159.2006.04163.x","volume":"99","author":"LE O\u2019Dell","year":"2006","unstructured":"O\u2019Dell, L. E., Manzardo, A. M., Polis, I., Stouffer, D. G. & Parsons, L. H. Biphasic alterations in serotonin-1B (5-HT1B) receptor function during abstinence from extended cocaine self-administration. J. Neurochem. 99, 1363\u20131376 (2006).","journal-title":"J. Neurochem."},{"key":"956_CR5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1734-1140(11)70695-8","volume":"63","author":"J Miszkiel","year":"2011","unstructured":"Miszkiel, J., Filip, M. & Przegali\u0144ski, E. Role of serotonin (5-HT)1B receptors in psychostimulant addiction. Pharmacol. Rep. 63, 1310\u20131315 (2011).","journal-title":"Pharmacol. Rep."},{"key":"956_CR6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pbb.2004.12.001","volume":"80","author":"JI Acosta","year":"2005","unstructured":"Acosta, J. I., Boynton, F. A., Kirschner, K. F. & Neisewander, J. L. Stimulation of 5-HT1B receptors decreases cocaine- and sucrose-seeking behavior. Pharm. Biochem. Beh. 80, 297\u2013307 (2005).","journal-title":"Pharm. Biochem. Beh."},{"key":"956_CR7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2013.08.014","volume":"76","author":"JL Neisewander","year":"2014","unstructured":"Neisewander, J. L., Cheung, T. H. & Pentkowski, N. S. Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development. Neuropharmacology 76, 301\u2013319 (2014).","journal-title":"Neuropharmacology"},{"key":"956_CR8","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1523\/JNEUROSCI.18-23-10078.1998","volume":"18","author":"LH Parsons","year":"1998","unstructured":"Parsons, L. H., Weiss, F. & Koob, G. F. Serotonin1B receptor stimulation enhances cocaine reinforcement. J. Neurosci. 18, 10078\u201310089 (1998).","journal-title":"J. Neurosci."},{"key":"956_CR9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00213-002-1145-8","volume":"163","author":"L Cervo","year":"2002","unstructured":"Cervo, L. et al. Stimulation of serotonin1B receptors induces conditioned place aversion and facilitates cocaine place conditioning in rats. Psychopharmacology 163, 142\u2013150 (2002).","journal-title":"Psychopharmacology"},{"key":"956_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(02)02873-X","volume":"459","author":"M Filip","year":"2003","unstructured":"Filip, M., Papla, I., Nowak, E., Czepiel, K. & Przegali\u0144ski, E. Effects of 5-HT1B receptor ligands microinjected into the ventral tegmental area on cocaine discrimination in rats. Eur. J. Pharmacol. 459, 239\u2013245 (2003).","journal-title":"Eur. J. Pharmacol."},{"key":"956_CR11","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1111\/j.1460-9568.2007.05568.x","volume":"25","author":"SK Barot","year":"2007","unstructured":"Barot, S. K., Ferguson, S. M. & Neumaier, J. F. 5-HT1B receptors in nucleus accumbens efferents enhance both rewarding and aversive effects of cocaine. Eur. J. Neurosci. 25, 3125\u20133131 (2007).","journal-title":"Eur. J. Neurosci."},{"key":"956_CR12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0091-3057(01)00717-1","volume":"71","author":"PJ Fletcher","year":"2002","unstructured":"Fletcher, P. J., Azampanah, A. & Korth, K. M. Activation of 5-HT1B receptors in the nucleus accumbens reduces self-administration of amphetamine on a progressive ratio schedule. Pharmacol. Biochem. Behav. 71, 717\u2013725 (2002).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"956_CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s002130050876","volume":"142","author":"PJ Fletcher","year":"1999","unstructured":"Fletcher, P. J. & Korth, K. M. Activation of 5-HT1B receptors in the nucleus accumbens reduces amphetamine-induced enhancement of responding for conditioned reward. Psychopharmacology 142, 165\u2013174 (1999).","journal-title":"Psychopharmacology"},{"key":"956_CR14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/cn400155t","volume":"5","author":"NS Pentkowski","year":"2014","unstructured":"Pentkowski, N. S. et al. Pharmacological evidence for an abstinence-induced switch in 5-HT1B receptor modulation of cocaine self-administration and cocaine-seeking behavior. ACS Chem. Neurosci. 5, 168\u2013176 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"956_CR15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.biopsych.2012.03.024","volume":"72","author":"NS Pentkowski","year":"2012","unstructured":"Pentkowski, N. S. et al. Protracted withdrawal from cocaine self-administration flips the switch on 5-HT1B receptor modulation of cocaine abuse-related behaviors. Biol. Psychiatry 72, 396\u2013404 (2012).","journal-title":"Biol. Psychiatry"},{"key":"956_CR16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1369-1600.2009.00162.x","volume":"14","author":"NS Pentkowski","year":"2009","unstructured":"Pentkowski, N. S., Acosta, J. I., Browning, J. R., Hamilton, E. C. & Neisewander, J. L. Stimulation of 5-HT1B receptors enhances cocaine reinforcement yet reduces cocaine-seeking behavior. Addiction Biol. 14, 419\u2013430 (2009).","journal-title":"Addiction Biol."},{"key":"956_CR17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00003495-199958020-00016","volume":"58","author":"C Spencer","year":"1999","unstructured":"Spencer, C., Gunasekara, N. & Hills, C. Zolmitriptan: a review of its use in migraine. Drugs 58, 347\u2013374 (1999).","journal-title":"Drugs"},{"key":"956_CR18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1152\/jn.01011.2010","volume":"106","author":"KC Murray","year":"2011","unstructured":"Murray, K. C. et al. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J. Neurophys. 106, 925\u2013943 (2011).","journal-title":"J. Neurophys."},{"key":"956_CR19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1365-2125.1997.00614.x","volume":"43","author":"E Seaber","year":"1997","unstructured":"Seaber, E. et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br. J. Clin. Pharmacol. 43, 579\u2013587 (1997).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"956_CR20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102413476372","volume":"33","author":"K Varnas","year":"2013","unstructured":"Varnas, K. et al. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers. Cephalalgia 33, 853\u2013860 (2013).","journal-title":"Cephalalgia"},{"key":"956_CR21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1517\/17425255.3.6.899","volume":"3","author":"B Peterlin","year":"2007","unstructured":"Peterlin, B. & Rapoport, A. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin. Drug Metab. Toxicol. 3, 899\u2013911 (2007).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"956_CR22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1742-1241.2000.tb10901.x","volume":"54","author":"SL Linder","year":"2000","unstructured":"Linder, S. L. & Dowson, A. J. Zolmitriptan provides effective migraine relief in adolescents. Int. J. Clin. Pract. 54, 466\u2013469 (2000).","journal-title":"Int. J. Clin. Pract."},{"key":"956_CR23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/00023210-200317110-00005","volume":"17","author":"AJ Dowson","year":"2003","unstructured":"Dowson, A. J. et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 17, 839\u2013851 (2003).","journal-title":"CNS Drugs"},{"key":"956_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s002130000488","volume":"152","author":"W Lynch","year":"2000","unstructured":"Lynch, W., Arizzi, M. & Marilyn, C. Effects of sex and the estrous cycle on regulation of intravenously self-administered cocaine in rats. Psychopharmacology 152, 132\u2013139 (2000).","journal-title":"Psychopharmacology"},{"key":"956_CR25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-002-1183-2","volume":"164","author":"W Lynch","year":"2002","unstructured":"Lynch, W., Roth, M. & Carroll, M. Biological basis of sex differences in drug abuse: Preclinical and clinical studies. Psychopharmacology 164, 121\u2013137 (2002).","journal-title":"Psychopharmacology"},{"key":"956_CR26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sj.npp.1300301","volume":"29","author":"M Hu","year":"2004","unstructured":"Hu, M., Crombag, H. S., Robinson, T. E. & Becker, J. B. Biological basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 29, 81\u201385 (2004).","journal-title":"Neuropsychopharmacology"},{"key":"956_CR27","unstructured":"Scott S. A selective serotonin1B receptor modulates cocaine self-administration in female rats regardless of estrous cycle phase. MSc thesis, Arizona State Univ. (2019)."},{"key":"956_CR28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ijnp\/pyx025","volume":"20","author":"R Garcia","year":"2017","unstructured":"Garcia, R., Cotter, A., Leslie, K., Olive, M. & Neisewander, J. L. Preclinical evidence that 5-HT1B receptor agonists show promise as medications for psychostimulant use disorders. Int. J. Neuropsychopharm. 20, 644\u2013653 (2017).","journal-title":"Int. J. Neuropsychopharm."},{"key":"956_CR29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/PL00005056","volume":"356","author":"GW Price","year":"1997","unstructured":"Price, G. W. et al. SB-216641 and BRL-15572-compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. N. S Arch. Pharmacol. 356, 312\u2013320 (1997).","journal-title":"N. S Arch. Pharmacol."},{"key":"956_CR30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/sj.bjp.0702059","volume":"125","author":"JV Selkirk","year":"1998","unstructured":"Selkirk, J. V. et al. SB-224289-a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br. J. Pharmacol. 125, 202\u2013208 (1998).","journal-title":"Br. J. Pharmacol."},{"key":"956_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1212\/WNL.48.3_Suppl_3.21S","volume":"48","author":"M Ferrari","year":"1997","unstructured":"Ferrari, M. 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B\/1D receptor agonists. Neurology 48, 21\u201324 (1997).","journal-title":"Neurology"},{"key":"956_CR32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0893-133X(95)00274-H","volume":"14","author":"NK Mello","year":"1996","unstructured":"Mello, N. K. & Negus, S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14, 375\u2013424 (1996).","journal-title":"Neuropsychopharmacology"},{"key":"956_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ddr.430260305","volume":"26","author":"KB Koe","year":"1992","unstructured":"Koe, K. B., Nielsen, J. A., Macor, J. E. & Heym, J. Biochemical and behavioral studies of the 5-HT1B receptor agonist, CP-94,253. Drug Dev. Res. 26, 241\u2013250 (1992).","journal-title":"Drug Dev. Res."},{"key":"956_CR34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pbb.2013.10.002","volume":"112","author":"KA Clissold","year":"2013","unstructured":"Clissold, K. A., Choi, E. & Pratt, W. E. Serotonin 1A, 1B, and 7 receptors of the rat medial nucleus accumbens differentially regulate feeding, water intake, and locomotor activity. Pharm. Biochem. Behav. 112, 96\u2013103 (2013).","journal-title":"Pharm. Biochem. Behav."},{"key":"956_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.08.007","volume":"352","author":"E Przegali\u0144ski","year":"2003","unstructured":"Przegali\u0144ski, E. Withdrawal from chronic cocaine up-regulates 5-HT1B receptors in the rat brain. Neurosci. Lett. 352, 169\u2013172 (2003).","journal-title":"Neurosci. Lett."},{"key":"956_CR36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2006.08.013","volume":"52","author":"BJ Hoplight","year":"2007","unstructured":"Hoplight, B. J., Vincow, E. S. & Neumaier, J. F. Cocaine increases 5-HT1B mRNA in rat nucleus accumbens shell neurons. Neuropharmacology 52, 444\u2013449 (2007).","journal-title":"Neuropharmacology"},{"key":"956_CR37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002130100778","volume":"157","author":"RM de Almeida","year":"2001","unstructured":"de Almeida, R. M., Nikulina, E. M., Faccidomo, S., Fish, E. W. & Miczek, K. A. Zolmitriptan-a 5-HT1B\/D agonist, alcohol, and aggression in mice. Psychopharmacology 157, 131\u2013141 (2001).","journal-title":"Psychopharmacology"},{"key":"956_CR38","first-page":"25","volume":"12","author":"K Saracheva","year":"2014","unstructured":"Saracheva, K. & Getova, D. Effects of 5-HT agonist eletriptan on passive avoidance and locomotor activity. Trakia J. Sci. 12, 25\u201328 (2014).","journal-title":"Trakia J. Sci."},{"key":"956_CR39","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/j.euroneuro.2018.11.423","volume":"29","author":"K Saracheva","year":"2019","unstructured":"Saracheva, K., Vasileva, L. & Getova, D. Effects of frovatriptan and almotriptan on locomotor activity in female rats with experimental model of migraine. Euro. Neuropsychopharmacol. 29, S266\u2013S267 (2019).","journal-title":"Euro. Neuropsychopharmacol."},{"key":"956_CR40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainres.2018.07.030","volume":"1698","author":"S Shahidi","year":"2018","unstructured":"Shahidi, S., Komaki, A., Sadeghian, R. & Soleimani, A. S. Effect of a 5-HT1D receptor agonist on the reinstatement phase of the conditioned place preference test and hippocampal long-term potentiation in methamphetamine-treated rats. Brain Res. 1698, 151\u2013160 (2018).","journal-title":"Brain Res."},{"key":"956_CR41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0165-6147(92)90054-A","volume":"13","author":"R Hen","year":"1992","unstructured":"Hen, R. Of mice and flies: commonalities among 5-HT receptors. Trends Pharmacol. Sci. 13, 160\u2013165 (1992).","journal-title":"Trends Pharmacol. Sci."},{"key":"956_CR42","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1471-4159.1993.tb03274.x","volume":"60","author":"G Maura","year":"1993","unstructured":"Maura, G., Thellung, S., Andrioli, G. C., Ruelle, A. & Raiteri, M. Release-regulating serotonin 5-HT1D autoreceptors in human cerebral cortex. J. Neurochemistry. 60, 1179\u20131182 (1993).","journal-title":"J. Neurochemistry."},{"key":"956_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(97)01404-0","volume":"2-3","author":"A Ghavami","year":"1997","unstructured":"Ghavami, A., Baruscotti, M. & Robinson, R. B. Adenovirus-mediated expression of 5-HT1B receptors in cardiac ventricle myocytes; coupling to inwardly rectifying K+ channels. Eur. J. Pharmacol. 2-3, 259\u2013266 (1997).","journal-title":"Eur. J. Pharmacol."},{"key":"956_CR44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2004.04.029","volume":"493","author":"IA Pullar","year":"2004","unstructured":"Pullar, I. A. et al. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. Eur. J. Pharmacol. 493, 85\u201393 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"956_CR45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","volume":"28","author":"Y Sari","year":"2004","unstructured":"Sari, Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci. Biobehav Rev. 28, 565\u2013582 (2004).","journal-title":"Neurosci. Biobehav Rev."},{"key":"956_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1749-6632.1990.tb16871.x","volume":"600","author":"JM Palacios","year":"1990","unstructured":"Palacios, J. M., Waeber, C., Hoyer, D. & Mengod, G. Distribution of serotonin receptors. Ann. N. Y. Acad. Sci. 600, 36\u201352 (1990).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"956_CR47","first-page":"143","volume":"40","author":"MW Hamblin","year":"1991","unstructured":"Hamblin, M. W. & Metcalf, M. A. Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol. Pharmacol. 40, 143\u2013148 (1991).","journal-title":"Mol. Pharmacol."},{"key":"956_CR48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0304-3940(98)00680-6","volume":"254","author":"P Bonaventure","year":"1998","unstructured":"Bonaventure, P., Langlois, X. & Leysen, J. E. Co-localization of 5-HT1B and 5-HT1D receptor mRNA in serotonergic cell bodies in guinea pig dorsal raphe nucleus: a double labeling in situ hybridization histochemistry study. Neurosci. Lett. 254, 113\u2013116 (1998).","journal-title":"Neurosci. Lett."},{"key":"956_CR49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer, D., Hannon, J. & Martin, G. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharm. Biochem. Behav. 71, 533\u2013554 (2002).","journal-title":"Pharm. Biochem. Behav."},{"key":"956_CR50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0006-8993(01)02823-2","volume":"915","author":"K Varnas","year":"2001","unstructured":"Varnas, K., Hall, H., Bonaventure, P. & Sedvall, G. Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR125743. Brain Res. 915, 47\u201357 (2001).","journal-title":"Brain Res."},{"key":"956_CR51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/1044-7431(92)90070-I","volume":"3","author":"MW Hamblin","year":"1992","unstructured":"Hamblin, M. W., McGuffin, R. W., Metcalf, M. A., Dorsa, D. M. & Merchant, K. M. Distinct 5-HT1B and 5-HT1D serotonin receptors in rat: Structural and pharmacological comparison of the two cloned receptors. Mol. Cell. Neurosci. 3, 579\u2013587 (1992).","journal-title":"Mol. Cell. Neurosci."},{"key":"956_CR52","first-page":"157","volume":"46","author":"D Hoyer","year":"1994","unstructured":"Hoyer, D. et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157\u2013203 (1994).","journal-title":"Pharmacol. Rev."},{"key":"956_CR53","first-page":"1","volume":"41","author":"N Adham","year":"1992","unstructured":"Adham, N., Romanienko, P., Hartig, P., Weinshank, R. L. & Branchek, T. The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D bet receptor. Mol. Pharmacol. 41, 1\u20137 (1992).","journal-title":"Mol. Pharmacol."},{"key":"956_CR54","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0028-3908(97)00036-1","volume":"36","author":"D Hoyer","year":"1997","unstructured":"Hoyer, D. & Martin, G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36, 419\u2013428 (1997).","journal-title":"Neuropharmacology"},{"key":"956_CR55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02247333","volume":"125","author":"TE Sipes","year":"1996","unstructured":"Sipes, T. E. & Geyer, M. A. Functional behavioral homology between rat 5-HT1B and guinea pig 5-HT1D receptors in the modulation of prepulse inhibition of startle. Psychopharmacology 125, 231\u2013237 (1996).","journal-title":"Psychopharmacology"},{"key":"956_CR56","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.biopsych.2013.11.022","volume":"76","author":"D Matuskey","year":"2015","unstructured":"Matuskey, D. et al. Reduction in brain 5-HT1B receptor availability in primarily cocaine-dependent human. Biol. Psychiatry 76, 816\u2013822 (2015).","journal-title":"Biol. Psychiatry"},{"key":"956_CR57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1526-4610.2011.02067.x","volume":"52","author":"D Sclar","year":"2012","unstructured":"Sclar, D. et al. Concomitant use of triptan, and SSRI or SNRI after the US food and drug administration alert on serotonin syndrome. Headache 52, 198\u2013203 (2012).","journal-title":"Headache"},{"key":"956_CR58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","volume":"148","author":"H Sternbach","year":"1991","unstructured":"Sternbach, H. The serotonin syndrome. Am. J. Psych. 148, 705\u2013713 (1991).","journal-title":"Am. J. Psych."},{"key":"956_CR59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.45.2.219","volume":"45","author":"R Bodner","year":"1995","unstructured":"Bodner, R., Lynch, T., Lewis, L. & Kahn, D. Serotonin syndrome. Neurology 45, 219\u2013223 (1995).","journal-title":"Neurology"},{"key":"956_CR60","first-page":"533","volume":"13","author":"J Volpi-Abadie","year":"2013","unstructured":"Volpi-Abadie, J., Kaye, A. M. & Kaye, A. D. Serotonin Syndrome. Ochsner J. 13, 533\u2013540 (2013).","journal-title":"Ochsner J."},{"key":"956_CR61","first-page":"48","volume":"9","author":"RW Evans","year":"2007","unstructured":"Evans, R. W. The FDA alert on serotonin syndrome analysis of 29 case reports. MedGenMed 9, 48 (2007).","journal-title":"MedGenMed"},{"key":"956_CR62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1526-4610.2006.00691.x","volume":"47","author":"R Shapiro","year":"2007","unstructured":"Shapiro, R. & Tepper, S. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 47, 266\u2013269 (2007).","journal-title":"Headache"},{"key":"956_CR63","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40263-012-0002-5","volume":"26","author":"P Rolan","year":"2012","unstructured":"Rolan, P. Drug interactions with triptans: Which are clinically significant? CNS Drugs 26, 949\u2013957 (2012).","journal-title":"CNS Drugs"},{"key":"956_CR64","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00004714-199504000-00005","volume":"15","author":"P Blier","year":"1995","unstructured":"Blier, P. & Bergeron, R. The safety of concomitant use of sumatriptan and antidepressant treatments. J. Clin. Psychopharm. 15, 106\u2013109 (1995).","journal-title":"J. Clin. Psychopharm."},{"key":"956_CR65","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1046\/j.1468-2982.1999.019007668.x","volume":"19","author":"GP Putnam","year":"1999","unstructured":"Putnam, G. P. et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 19, 668\u2013675 (1999).","journal-title":"Cephalalgia"},{"key":"956_CR66","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.1212\/WNL.0000000000008685","volume":"94","author":"J Robblee","year":"1999","unstructured":"Robblee, J., Butterfield, R., Kang, A. & Smith, J. Triptan and ergotamine overdoses in the United States: analysis of the National Poison Data System. Neurology 94, e1460\u2013e1469 (1999).","journal-title":"Neurology"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00956-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T06:58:26Z","timestamp":1696489106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1038\/s41398-020-00956-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"type":"electronic","value":"2158-3188"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"266"}}